In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contribution of different players of the tumor microenvironment, with a particular focus on different immune cell subsets and their essential role during the development of the disease, the response to standard chemotherapy, and to emerging immunotherapeutic approaches. By reviewing the molecular and genetic features of ovarian and breast cancer subtypes, we report on the multitude of factors influencing treatment outcome, with a particular interest on the possible influence of the immune system (i.e., tumor infiltrating lymphocytes, T cells, regulatory T cells, myeloid-derived suppressor cells, dendritic cells, macrophages, B cells, tumor-associated neutrophils). Finally, we discuss emerging immune targets and novel therapeutic modalities that are likely to profoundly influence clinical outcome and prognosis of breast and ovarian cancers in the next future.
The Immune Landscape in Women Cancers / Timperi, E.; Vissio, E.; Marchio, C.; Romano, E.. - (2020), pp. 215-249. - CANCER TREATMENT AND RESEARCH. [10.1007/978-3-030-38862-1_8].
The Immune Landscape in Women Cancers
Timperi E.Primo
Writing – Review & Editing
;
2020
Abstract
In this chapter, we summarize the latest findings in the field of immuno-oncology of women cancers, particularly ovarian and breast tumors. We describe the relationship between immune parameters and clinical outcomes by evaluating the contribution of different players of the tumor microenvironment, with a particular focus on different immune cell subsets and their essential role during the development of the disease, the response to standard chemotherapy, and to emerging immunotherapeutic approaches. By reviewing the molecular and genetic features of ovarian and breast cancer subtypes, we report on the multitude of factors influencing treatment outcome, with a particular interest on the possible influence of the immune system (i.e., tumor infiltrating lymphocytes, T cells, regulatory T cells, myeloid-derived suppressor cells, dendritic cells, macrophages, B cells, tumor-associated neutrophils). Finally, we discuss emerging immune targets and novel therapeutic modalities that are likely to profoundly influence clinical outcome and prognosis of breast and ovarian cancers in the next future.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.